

Prior to examination of the above-identified new national phase patent application, please amend the application, as follows:

**In the Specification**

Please insert on page 1, between the title of the application and the first paragraph, the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U. S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02589 filed August 2, 2000, which in turn claims priority of German Patent Application No. 199 37 264.0 filed August 6, 1999.

**In the Claims**

Please amend claims 1-12 and 14 to read as follows:

1. A F<sub>V</sub> antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.
2. The F<sub>V</sub> antibody construct according to claim 1, wherein the CD16 receptor is derived from NK cells.
3. The F<sub>V</sub> antibody construct according to claim 1, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
4. The F<sub>V</sub> antibody construct according to claim 1, wherein one binding site is present each.
5. The F<sub>V</sub> antibody construct according to claim 4, encoded by the expression vector pKTDI6-30 (DEM 12960).
6. The F<sub>V</sub> antibody construct according to claim 1, wherein two binding sites are present for

each.

7. An expression vector, coding for the F<sub>v</sub> antibody construct according to claim 1.
8. The expression vector according to claim 7, which is pKID16-30 (DSM 12960).
9. A transformant, containing the expression vector according to claim 7.
10. A method of producing the F<sub>v</sub> antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.
11. A kit comprising:
  - (a) an F<sub>v</sub> antibody construct according to the invention and/or
  - (b) an expression vector according to the invention, and
  - (c) common auxiliary substances, such as buffers, solvents, carriers, controls and markers,
 wherein one or more representatives of the individual components may be present.
12. Use of the F<sub>v</sub> antibody construct according to claim 1 for lysis of cells expressing CD30 surface proteins.
14. Use according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

Please add claims 15-18.

15. The F<sub>v</sub> antibody construct according to claim 2, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
16. An expression vector, coding for the F<sub>v</sub> antibody construct according to claim 15.